Eli Lilly 2009 Annual Report Download - page 22

Name Age Offices and Business Experience
John H. Johnson 52
Senior Vice President and President, Lilly Oncology (since November 2009). Mr. Johnson was
chief executive officer and a director of ImClone Systems Inc. from 2007 until its acquisition
by Lilly in November 2008. From 2002 to 2007 he served in various executive positions at
Johnson & Johnson, including Group Chairman of that company’s worldwide
biopharmaceuticals unit from 2005 to 2007. He first joined Johnson & Johnson in 1988.
In 2000, Mr. Johnson left J&J to serve as chief executive officer of Parkstone Medical
Information Systems, a start-up company that developed a hand-held device for doctors to
write prescriptions. That company filed for bankruptcy protection in 2001.
Jan M. Lundberg, Ph.D. 56
Executive Vice President, Science and Technology and President, Lilly Research Laboratories
(since January 2010). From 2002 until he joined Lilly in January 2010, Dr. Lundberg was
executive vice president and head of discovery research at AstraZeneca.
Susan Mahony, Ph.D. 45 Senior Vice President, Human Resources (since May 2009)
Anne Nobles 53 Senior Vice President, Enterprise Risk Management (since April 2009) and Chief Ethics and
Compliance Officer (since June 2007)
Steven M. Paul, M.D. 59 Executive Vice President, Science and Technology and President, Lilly Research Laboratories
(since July 2003; retiring February 28, 2010)
Barton R. Peterson 51
Senior Vice President, Corporate Affairs and Communications (since June 2009). Mr. Peterson
served as mayor of Indianapolis, Indiana from 2000 to 2007. From 2008 to 2009, he was
managing director at Strategic Capital Partners, LLC and distinguished visiting professor of
public policy at Ball State University.
Derica W. Rice 45 Executive Vice President, Global Services (since January 2010) and Chief Financial Officer
(since May 2006)
Jeffrey N. Simmons 42 Senior Vice President and President, Elanco Animal Health (since January 2008)
Jacques Tapiero 51 Senior Vice President and President, Emerging Markets (since January 2010)
Employees
At the end of 2009, we employed approximately 40,360 people, including approximately 20,300 employees
outside the United States. A substantial number of our employees have long records of continuous
service.
Financial Information Relating to Business Segments and Classes of Products
You can find financial information relating to our business segments and classes of products in Item 8 of
this Form 10-K, “Segment Information.” That information is incorporated here by reference.
The relative contribution of any particular product to our consolidated net sales changes from year to year.
This is due to several factors, including the introduction of new products by us and by other manufacturers
and the introduction of generic pharmaceuticals upon patent expirations. In addition, margins vary for our
different products due to various factors, including differences in the cost to manufacture and market the
products, the value of the products to the marketplace, and government restrictions on pricing and
reimbursement. Our major product sales are generally not seasonal.
Financial Information Relating to Foreign and Domestic Operations
You can find financial information relating to foreign and domestic operations in Item 8, “Segment
Information.” That information is incorporated here by reference. To date, our overall operations abroad
have not been significantly deterred by local restrictions on the transfer of funds from branches and
subsidiaries located abroad, including the availability of U.S. dollar exchange. We cannot predict what
effect these restrictions or the other risks inherent in foreign operations, including possible nationaliza-
tion, might have on our future operations or what other restrictions may be imposed in the future. In
addition, changing currency values can either favorably or unfavorably affect our financial position,
10
FORM 10-K